The approval paves the way for Sanofi's insulin and GLP-1 combination therapy, which is due for final FDA action in August.
FDA has approved lixisenatide, the GLP-1 receptor agonist that was the first diabetes therapy submitted to regulators with full cardiovascular safety results in hand.
Sanofi, which plans to market the drug as Adlyxin, announced the approval Wednesday. The therapy has been sold as Lyxumia in more than 60 countries, including most of Europe, as well as Mexico and India, which have high rates of diabetes.
Lixisenatide is given at mealtime once daily by injection with a prefilled pen. Patients take a 10 mcg dose for 2 weeks before moving to a 20 mcg dose. This phased-in dosing is designed to limit nausea, which can be a side effect of GLP-1 receptor agonists as patients adjust to the therapy.
The drug blocks the effect of glucagon-like peptide (GLP-1) on pancreatic cells that, when functioning normally, regulate insulin secretion. Lixisenatide boosts glucose-dependent insulin secretion.
Approval was based on clinical results from Sanofi’s GetGoal program, as well as CV results from the ELIXA trial presented at the June 2015 meeting of the American Diabetes Association (ADA) in Boston. Sanofi provided FDA with results from 11 multinational trials that showed lixisenatide reduced glycated hemoglobin (A1C) from 0.7% to 1.0% and, after 24 weeks, allows more patients to bring A1C below 7.0% than placebo. ELIXA found that lixisenatide was safe, with no CV benefits but no harmful effects, either.
From our ADA coverage: Novo’s Tresiba, Insulin GLP-1 combos draw interest
The action gives Sanofi approval of both components of its GLP-1 and insulin combination therapy, which received a recommendation from an FDA advisory panel in late May. Full results for the therapy, which pairs lixisenatide with Sanofi’s mainstay insulin, Lantus, were presented at the 2016 ADA meeting in New Orleans. The combination met its primary endpoints in phase 3 trials, and Julio Rosenstock, MD, presented findings that show the combination performs better than the sum of its parts.
An FDA decision on the combination is due in August, while a decision on a competing insulin / GLP-1 combination from Novo Nordisk is expected by September.
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management
May 10th 2022On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.
Listen
How Can Employers Leverage the DPP to Improve Diabetes Rates?
February 15th 2022On this episode of Managed Care Cast, Jill Hutt, vice president of member services at the Greater Philadelphia Business Coalition on Health, explains the Coalition’s efforts to reduce diabetes rates through the Diabetes Prevention Program (DPP).
Listen